From: In vitro chemoresponse in metachronous pairs of gyneclologic cancers
Number of pairs | Primary median (IQR) RI SCORE | Recurrent median (IQR) RI SCORE | p | |
---|---|---|---|---|
Carboplatin | 46 | 2(1–3) | 1(1–2) | 0.06 |
Carboplatin/Gemcitabine | 35 | 2(1–3) | 2(2–3) | 0.36 |
Carboplatin/Paclitaxel | 41 | 3(1–3) | 2(1–3) | 0.67 |
Cisplatin | 42 | 2(1–2) | 2(1–2) | 1.00 |
Docetaxel | 42 | 1(1–2) | 1(1–2) | 0.51 |
Doxorubicin | 49 | 1(1–2) | 1(1–2) | 0.89 |
Etoposide | 39 | 2(1–2) | 2(1–2) | 0.21 |
Gemcitabine | 48 | 1(1–2) | 1(1–2) | 0.33 |
Ifosfamide | 30 | 2(1–2) | 2(1–2) | 0.83 |
Paclitaxel | 47 | 2(1–3) | 1(1–2) | 0.04 |
Topotecan | 52 | 1.5(1–2) | 1(1–2) | 0.70 |